1、novotech-APRIL 10,2024Endometrial cancer-Global Clinical Trial Landscape(2024)Countries like the United States,Mainland China,Spain,Australia,and South Korea emerged as top locations for conducting trialsAsia-Pacific showed faster recruitment dura-tions and patient recruitment ratesUterine cancer,pr

2、imarily EC,ranks as the fourthleading cause of death globally among gynecologi-cal malig-nanciesSome newly FDA-approved drugs for EC are Jemperli for primary advanced or recurrent EC and Keytruda with Lenvima for advanced carcinomaThe EC treatment market ofers diverse products by companies including

3、 AnaptysBio Inc.,Eisai Co.Ltd.,Merck&Co.Inc.,Pfizer Inc.,and AstraZeneca plcMultiple ongoing Phase III trials by AstraZeneca plc.demonstrate continued eforts to enhance EC treatment through antibody and small molecule therapiesECGLOBAL DEATHSThe content of this publication is proprietary to Novotech

4、 Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and n

5、on-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result

6、in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-ENDOMETRIAL CANCER(EC)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)#DYK Did youknow?TRIAL CONTRIBUTIONS10%ROW60%NORTH AMERICA&EUROPE30%ASIA-PACIFICGlobally,EC accounted for nearly 420,3